

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

## **VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME**

This is a voluntary announcement made by Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”).

Reference is made to the announcement of the Company dated 26 October 2022 (the “**Announcement**”), in relation to, among others, the 2022 share award scheme adopted by the Company (the “**Share Award Scheme**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement. During the period from 29 May 2023 to 7 June 2023, the Trustee purchased a total number of 4,500,000 shares of the Company (the “**Shares**”) on the market for the purpose of the Share Award Scheme. Details are set out below:

Transaction dates:	30 May 2023, 31 May 2023, 1 June 2023, 6 June 2023 and 7 June 2023
Total number of Shares purchased:	4,500,000 Shares
Shares purchased as a percentage of the total number of Shares in issue as at the date of this announcement:	approximately 0.05%
Average consideration per Share purchased:	approximately HK\$0.7429

## **About Sihuan Pharmaceutical**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system.

Adhering to the overall strategic objective of “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China. With the gradual achievement of the Group’s goals in transformation to R&D and innovation, medical aesthetics and other high-growth new business and the implementation of the strategy of carving-out certain generic drug business, the management of the Company has strong confidence in the business development and prospects of the Group.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 7 June 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*